🧔♂️ A friendly human may check it before it goes live. More news here
SG-based medtech firm UltraGreen.ai nets $188m at $1.3b valuation
UltraGreen.ai has signed a US$188 million investment agreement led by 65 Equity Partners and Vitruvian Partners, with participation from August Global Partners, at an equity valuation of US$1.3 billion.
The Singapore-based company provides fluorescence-guided surgical technologies and supplies indocyanine green (ICG), a dye used in over 90% of such procedures globally.
The funds will be used to expand its AI-powered surgical imaging platform and technology portfolio.
The investment also marks a partnership with international investors as the company seeks to broaden its market presence, particularly in Asia-Pacific.
Citigroup Global Markets Singapore acted as financial adviser for the transaction.
🔗 Source: UltraGreen.ai
🧠 Food for thought
Implications, context, and why it matters.
Company valuation significantly exceeds current market size, indicating ambitious growth expectations
- UltraGreen.ai’s $1.3 billion valuation dwarfs the entire fluorescence-guided surgery systems market, which research firms valued between $74.57 million and $124.27 million in 2023-2025 123.
- This valuation gap suggests investors are betting on market expansion, given that multiple research reports project the FGS market to grow at compound annual growth rates between 14.1% and 16.26% through 2030-2032 12.
- UltraGreen’s claim as the “world’s largest provider of ICG” used in 90% of FGS procedures worldwide positions them to capture significant value as this small but rapidly growing market scales up.
- The substantial premium likely reflects investor confidence in UltraGreen’s ability to expand beyond traditional surgical imaging into AI-powered surgical intelligence and decision support systems across multiple surgical specialties.
Strategic timing aligns with accelerating adoption of precision surgical technologies
- The investment comes as clinical evidence expands for fluorescence-guided surgery benefits, with recent FDA clearances like pegulicianine for breast lumpectomy showing detection of residual disease in 7.6% of patients post-excision 2.
- Market research indicates near-infrared fluorescence systems held 72% market share in 2024, while multispectral platforms are growing at 19.8% CAGR, suggesting technology evolution is accelerating 2.
- The International Agency for Research on Cancer reported 20 million new cancer cases globally in 2022, creating sustained demand for advanced surgical technologies that improve precision in tumor removal 1.
- UltraGreen’s expansion from basic ICG supply to AI-powered quantification software positions them to benefit from the broader trend toward data-driven surgical decision support, addressing the market shift from simple visualization to comprehensive surgical intelligence.
